Home
EOLS
EOLS News

Latest Evolus Inc. (EOLS) News on November 17, 2024

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Zacks

3 days ago

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.

8 days ago

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Evolus Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

9 days ago

Evolus Third Quarter 2024 Earnings: Misses Expectations

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

GuruFocus.com

10 days ago

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Zacks

10 days ago

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus Reports Third Quarter 2024 Results

Business Wire

11 days ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Business Wire

16 days ago

Evolus to Participate in Stifel 2024 Healthcare Conference

MT Newswires

17 days ago

Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Business Wire

17 days ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Zacks

17 days ago

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Zacks

18 days ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Business Wire

19 days ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Business Wire

25 days ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Simply Wall St.

a month ago

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

GuruFocus.com

a month ago

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Business Wire

2 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Insider Monkey

3 months ago

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

4 months ago

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Investor's Business Daily

4 months ago

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Business Wire

4 months ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Business Wire

4 months ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Business Wire

4 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire

4 months ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Pharmaceutical Technology

4 months ago

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Evolus to Report Second Quarter Financial Results on July 31, 2024

Business Wire

4 months ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Business Wire

5 months ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

MT Newswires

5 months ago

Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Business Wire

5 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Simply Wall St.

5 months ago

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Business Wire

5 months ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

5 months ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

CNW Group

5 months ago

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

GlobeNewswire

5 months ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

CNW Group

5 months ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Newsfile

5 months ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Camber Energy Announces Passing of Director Lawrence Fisher

ACCESSWIRE

5 months ago

Camber Energy Announces Passing of Director Lawrence Fisher

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

GlobeNewswire

5 months ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

5 months ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 06/07/2024

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space

WWD

6 months ago

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Zacks

6 months ago

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Business Wire

6 months ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

GuruFocus.com

6 months ago

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)

GuruFocus.com

6 months ago

Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

Business Wire

6 months ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

Business Wire

6 months ago

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript

Insider Monkey

6 months ago

Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Evolus Inc Earnings Call

GuruFocus.com

6 months ago

Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Zacks

6 months ago

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth

GuruFocus.com

6 months ago

Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth

Evolus Reports First Quarter 2024 Results and Provides Business Update

Business Wire

6 months ago

Evolus Reports First Quarter 2024 Results and Provides Business Update

The 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%

Simply Wall St.

6 months ago

The 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%

Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?

Zacks

7 months ago

Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?

Evolus to Report First Quarter Financial Results on May 7, 2024

Business Wire

7 months ago

Evolus to Report First Quarter Financial Results on May 7, 2024

11 Best Low Price Pharma Stocks To Invest In

Insider Monkey

7 months ago

11 Best Low Price Pharma Stocks To Invest In

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

Business Wire

7 months ago

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company

Simply Wall St.

7 months ago

Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

8 months ago

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

10 Stocks George Soros and Insiders Are Crazy About

Insider Monkey

8 months ago

10 Stocks George Soros and Insiders Are Crazy About

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?

Zacks

8 months ago

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Business Wire

8 months ago

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report

Simply Wall St.

8 months ago

Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report

Evolus Full Year 2023 Earnings: In Line With Expectations

Simply Wall St.

8 months ago

Evolus Full Year 2023 Earnings: In Line With Expectations

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Evolus Inc Earnings Call

Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024

GuruFocus.com

8 months ago

Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Business Wire

8 months ago

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

11 Best Small Cap Pharma Stocks to Invest In

Insider Monkey

8 months ago

11 Best Small Cap Pharma Stocks to Invest In

Evolus Announces Results from European Head-to-Head Filler Trial

Business Wire

9 months ago

Evolus Announces Results from European Head-to-Head Filler Trial

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Business Wire

9 months ago

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Business Wire

9 months ago

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Inc Director Karah Parschauer Sells 11,931 Shares

GuruFocus.com

9 months ago

Evolus Inc Director Karah Parschauer Sells 11,931 Shares

Oceaneering International (OII) Gains But Lags Market: What You Should Know

Zacks

10 months ago

Oceaneering International (OII) Gains But Lags Market: What You Should Know

Why IBM's new retirement plan has the industry buzzing

Yahoo Finance Video

10 months ago

Why IBM's new retirement plan has the industry buzzing

Archrock Increases Quarterly Cash Dividend

GlobeNewswire

10 months ago

Archrock Increases Quarterly Cash Dividend

Evolus Insider Ups Holding By 210% During Year

Simply Wall St.

10 months ago

Evolus Insider Ups Holding By 210% During Year

Cinemark’s Annual Oscar® Movie Week Festival Brings Prestigious Hollywood Films to Auditoriums Across the Nation

Business Wire

10 months ago

Cinemark’s Annual Oscar® Movie Week Festival Brings Prestigious Hollywood Films to Auditoriums Across the Nation

Century Communities Announces Acquisition of Greater Nashville Builder: Landmark Homes of Tennessee, Inc.

PR Newswire

10 months ago

Century Communities Announces Acquisition of Greater Nashville Builder: Landmark Homes of Tennessee, Inc.

Northwest Bancshares Inc Reports Mixed Q4 Results Amid Interest Rate and Liquidity Challenges

GuruFocus.com

10 months ago

Northwest Bancshares Inc Reports Mixed Q4 Results Amid Interest Rate and Liquidity Challenges

LTC Properties Inc's Dividend Analysis

GuruFocus.com

10 months ago

LTC Properties Inc's Dividend Analysis

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

Business Wire

10 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 Overlooked Stocks Poised for Extraordinary 10X Growth

InvestorPlace

10 months ago

3 Overlooked Stocks Poised for Extraordinary 10X Growth

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESSWIRE

10 months ago

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

Vista Outdoor to Release Third Quarter Fiscal Year 2024 Financial Results

Business Wire

10 months ago

Vista Outdoor to Release Third Quarter Fiscal Year 2024 Financial Results

Is There Now An Opportunity In LKQ Corporation (NASDAQ:LKQ)?

Simply Wall St.

10 months ago

Is There Now An Opportunity In LKQ Corporation (NASDAQ:LKQ)?

Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?

Zacks

10 months ago

Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?

Wolverine (WWW) Announces Its Preliminary Results for 2023

Zacks

10 months ago

Wolverine (WWW) Announces Its Preliminary Results for 2023

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

Simply Wall St.

10 months ago

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

Share on Social Networks: